City Therapeutics, Inc. (CTY)
NYSE
Closed
Oct 20, 2026
Day's Range
20.0152 wk Range
20.01Overview - CTY - City Therapeutics, Inc.
Key Statistics
Valuation
Enterprise Value
261.93M
Price / Sales (TTM)
‪78.61‬
EV / EBITDA
‪-3.15‬
Profitability
Profit Margin
‪0.00%‬
Operating Margin
‪-804.19%‬
Ownership
Shares Outstanding
50.33M
Float
3.08M
Price stats
50-Day Avg
‪22.40‬
200-Day Avg
‪22.40‬
Peers - CTY - City Therapeutics, Inc.
Peer Comparison
Compared with companies in Biotechnology listed on NYSE.
- CTYNYSECity Therapeutics, Inc.1.12BMarket Cap+0.00%52-week change—P/E (Trailing)‪0.00%‬Profit Margin
- BIONYSEBio-Rad Laboratories Inc.9.45BMarket Cap+8.99%52-week change44.83P/E (Trailing)‪8.58%‬Profit Margin
- BSTNYSEBlackRock Science and Technology Trust1.76BMarket Cap+21.83%52-week change7.02P/E (Trailing)‪0.00%‬Profit Margin
- BHVNNYSEBiohaven Ltd.1.71BMarket Cap-56.21%52-week change-1.66P/E (Trailing)‪0.00%‬Profit Margin
- BCXNYSEBlackRock Resources & Commodities Strategy Trust991.85MMarket Cap+22.29%52-week change4.66P/E (Trailing)‪0.00%‬Profit Margin
- ANRONYSEAlto Neuroscience Inc.895.50MMarket Cap+52.45%52-week change-10.42P/E (Trailing)‪0.00%‬Profit Margin
- ATTONYSEAttovia Therapeutics Inc.634.09MMarket Cap-57.67%52-week change-5.85P/E (Trailing)‪0.00%‬Profit Margin
Profile Summary - CTY - City Therapeutics, Inc.
About
City Therapeutics, Inc. is a clinical-stage biotechnology company developing RNA interference therapeutics that selectively silence the expression of disease-relevant proteins. Its platform is designed to address biological targets that may be difficult to modulate with conventional medicines, with an emphasis on…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
